🔍

DRREDDY - Dr Reddy's Labs

📊 NSE: DRREDDY 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:40

📢 Recent Corporate Announcements

Dr. Reddy's First to Secure Health Canada Approval for Generic Semaglutide Injection

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 29 Apr 2026, 09:11 AM

Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, making it the first generic player to receive marketing authorization in Canada. Canada is currently the world's second-largest market for Semaglutide, serving a diabetic population of approximately 3.9 million people, or 9.7% of the population. The approval covers 2 mg and 4 mg pens and was achieved ahead of the regulatory review target date. The company will utilize its 100% in-house API production, which strengthens its competitive position and margins in the complex peptide-based therapeutics space.

First generic company to receive marketing authorization for Semaglutide Injection in Canada.
Canada represents the world's second-largest market for Semaglutide treatments per IQVIA data.
Targets a Canadian patient base of 3.9 million people living with diagnosed diabetes.
Approval includes 2 mg / pen and 4 mg / pen dosages with 100% in-house API manufacturing.
Authorization was granted ahead of Health Canada's official review target date.

💡 This approval establishes Dr. Reddy's as a frontrunner in the high-growth generic GLP-1 segment in a major regulated market. Investors should view this as a significant positive for long-term revenue growth and a validation of the company's complex generic capabilities.

Dr. Reddy's to Announce Q4 and FY26 Results on May 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Apr 2026, 02:39 PM

Dr. Reddy's Laboratories has scheduled the release of its financial results for the fourth quarter and the full fiscal year ended March 31, 2026, for May 12, 2026. The results will be announced following a Board Meeting on the same day. An earnings call is slated for 19:30 PM IST (10:00 AM ET) to discuss the company's financial performance with the management. This announcement serves as a standard regulatory notification for the upcoming reporting timeline.

Q4 and full year FY26 results to be released on Tuesday, May 12, 2026
Earnings call scheduled for 19:30 PM IST / 10:00 AM ET on the same day
Results will be published after the conclusion of the Board Meeting
Audio and transcripts of the call will be available on the company website and stock exchanges

💡 Investors should mark May 12, 2026, on their calendars to review the financial performance and management commentary. No immediate action is required until the actual results are published.

Dr. Reddy's Clarifies Status of Semaglutide Injection Approval from Health Canada

🔵 WATCH ⭐ 7/10

REGULATORY 📅 24 Apr 2026, 09:36 AM

Dr. Reddy's Laboratories has clarified that it is still awaiting the 'Notice of Compliance' for its Semaglutide Injection from Health Canada, confirming recent media reports. However, the company achieved a regulatory milestone by receiving 'Drug Identification Numbers (DINs)' for the product on April 22, 2026. This clarification follows significant stock price movement on April 23, 2026, and a subsequent inquiry from the National Stock Exchange. The company maintains that there is no undisclosed material information and continues to engage with Canadian authorities for final approval.

Confirmed awaiting 'Notice of Compliance' (NOC) for Semaglutide Injection in Canada
Received 'Drug Identification Numbers (DINs)' from Health Canada on April 22, 2026
Clarification issued following stock price volatility on April 23, 2026
Semaglutide is identified as a major near-term trigger for the company's expansion
Company states no material impact currently as regulatory review is ongoing

💡 Investors should closely monitor the final 'Notice of Compliance' from Health Canada, as this will be the definitive catalyst for market entry. While the receipt of DINs is a positive step, the stock may experience volatility until the final approval is officially granted.

Dr. Reddy's Receives DINs for Semaglutide in Canada; Awaits Final Approval

🔵 WATCH ⭐ 7/10

REGULATORY 📅 24 Apr 2026, 09:13 AM

Dr. Reddy's Laboratories clarified that it has received Drug Identification Numbers (DINs) for its Semaglutide Injection from Health Canada on April 22, 2026. However, the company is still awaiting the final 'Notice of Compliance' required for a commercial launch in the Canadian market. This clarification follows media reports regarding a delay in a major near-term trigger for the company. Semaglutide is a key product in the high-growth GLP-1 space, making its regulatory progress a significant event for investors.

Received Drug Identification Numbers (DINs) from Health Canada on April 22, 2026
Still awaiting final 'Notice of Compliance' for Semaglutide Injection approval
Clarification issued following a CNBC TV18 news report dated April 23, 2026
Company remains committed to launching the product in Canada upon final approval

💡 Investors should monitor for the final 'Notice of Compliance' from Health Canada, as it is the final hurdle before commercialization. The receipt of DINs is a positive regulatory milestone, but the stock's near-term movement depends on the final launch timeline.

Dr. Reddy's Board to Consider Final Dividend for FY 2025-26

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 16 Apr 2026, 03:43 PM

Dr. Reddy's Laboratories has officially informed stock exchanges that its Board of Directors will meet to consider recommending a final dividend for the financial year 2025-26. This notification follows a preliminary intimation provided by the company on March 23, 2026. The meeting will determine the potential payout to shareholders, adhering to SEBI Regulation 29. Investors are currently awaiting the specific dividend amount and the associated record date for eligibility.

Board of Directors to evaluate final dividend recommendation for FY 2025-26
Announcement follows a prior intimation issued on March 23, 2026
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements 2015
Final dividend amount and record date to be announced post-meeting

💡 Investors should wait for the official board meeting outcome to assess the dividend yield. No immediate action is required as this is a routine procedural announcement.

Dr. Reddy's Russian Subsidiary Receives Final Tax Penalty of INR 11.40 Million

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 14 Apr 2026, 09:17 PM

Dr. Reddy's Laboratories LLC, a step-down subsidiary in Russia, has received a final penalty decision from the Russian Tax Authority. The penalty arises from the re-classification of marketing services as taxable services for Value Added Tax (VAT) purposes. The final penalty amount is RUB 9.27 million (approximately INR 11.40 million), which is a reduction from the initial claim of RUB 20.09 million. The company has confirmed that this penalty will have no material impact on its consolidated financials or operations.

Final penalty of RUB 9.27 million (INR 11.40 million) imposed by the Interdistrict Inspectorate of the Federal Tax Service of Russia.
The penalty amount was reduced by over 50% from the original claim of RUB 20.09 million (INR 24.50 million).
The issue pertains to the re-classification of marketing services as taxable services under Russian VAT laws.
Management states the penalty has no material impact on the company's overall financial health or business activities.

💡 This is a minor regulatory development with negligible financial impact on a company of Dr. Reddy's scale. Investors should treat this as a routine disclosure and focus on broader operational performance.

Dr. Reddy's Submits SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 04:02 PM

Dr. Reddy's Laboratories has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Bigshare Services Private Limited, confirms the processing of dematerialization requests for the quarter ended March 31, 2026. It verifies that security certificates were mutilated and cancelled after due verification within the mandated 15-day timeframe. This is a standard administrative filing required for listed companies in India.

Compliance certificate submitted for the quarter ended March 31, 2026
Confirmation provided by Registrar and Share Transfer Agent, Bigshare Services Private Limited
Securities received for dematerialization were processed and listed on stock exchanges
Physical certificates were mutilated and cancelled within the 15-day regulatory window

💡 This is a routine regulatory filing with no impact on the company's financial performance or stock valuation. No action is required from investors.

Dr. Reddy's Allots 3,675 Equity Shares Under Employee Stock Option Scheme

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Mar 2026, 02:33 PM

Dr. Reddy's Laboratories has allotted 3,675 equity shares of Re. 1 each to eligible employees on March 26, 2026, following the exercise of stock options. The allotment was made under the Dr. Reddy’s Employees ADR Stock Options Scheme, 2007. The exercise prices for these shares were set at Re. 1 for 575 shares and Rs. 735.80 for 3,100 shares. This routine issuance results in a marginal increase in the company's total paid-up share capital to Rs. 83,46,56,970.

Allotment of 3,675 fully paid-up equity shares of face value Re. 1 each
Exercise prices included 575 shares at Re. 1 and 3,100 shares at Rs. 735.80 per share
Total paid-up share capital increased to Rs. 83,46,56,970 across 83,46,56,970 shares
Shares issued under the Dr. Reddy’s Employees ADR Stock Options Scheme, 2007
New shares rank pari passu with existing equity shares of the company

💡 No action is required as this is a routine administrative allotment with negligible equity dilution. Investors should remain focused on the company's fundamental earnings and product pipeline.

Dr. Reddy's Updates Code for Fair Disclosure of Price Sensitive Information

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Mar 2026, 07:26 PM

Dr. Reddy's Laboratories has amended its 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information' (UPSI) effective March 24, 2026. The revised code aligns with SEBI (Prohibition of Insider Trading) Regulations to ensure uniform and universal dissemination of material information. Key updates include the formal designation of the Head of Investor Relations as the Chief Investor Relations Officer and stricter protocols for handling UPSI on a 'need to know' basis. The company also confirmed the maintenance of a structured digital database to track information sharing for a minimum of eight years.

Board of Directors approved the amended disclosure code on March 24, 2026, to comply with SEBI PIT Regulations.
Mandates that any inadvertently disclosed UPSI must be made public within 24 hours of identification.
Strictly prohibits the disclosure of material non-public information through any social media platforms.
Requires a structured digital database containing PAN or other identifiers of persons receiving UPSI to be preserved for 8 years.
Designates the Head of Investor Relations as the Chief Investor Relations Officer to prevent selective disclosure.

💡 This is a routine regulatory update focused on corporate governance and transparency. No immediate action is required as it does not impact the company's financial fundamentals or business operations.

Dr. Reddy's to Consider Q4 & FY26 Results on May 12; Trading Window Closed from March 25

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 23 Mar 2026, 05:37 PM

Dr. Reddy's Laboratories has scheduled a Board of Directors meeting on Tuesday, May 12, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026. In accordance with SEBI insider trading regulations, the trading window for the company's securities will be closed from March 25, 2026, through May 14, 2026. This is a routine regulatory announcement preceding the annual financial disclosure. Investors should mark May 12 as the key date for the company's performance assessment.

Board meeting scheduled for May 12, 2026, to approve Q4 and full-year FY26 results.
Trading window closure period set from March 25, 2026, to May 14, 2026.
The meeting will cover both Audited Standalone and Consolidated Financial Results.
Announcement made in compliance with SEBI (LODR) and SEBI (PIT) Regulations.

💡 No immediate action is required as this is a routine administrative filing. Investors should monitor the stock for potential volatility as the May 12 earnings date approaches.

Dr. Reddy's Launches India's First Generic Semaglutide 'Obeda' at INR 4,200/Month

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Mar 2026, 01:59 PM

Dr. Reddy's has launched Obeda®, India's first DCGI-approved generic Semaglutide injection for Type 2 Diabetes, marking a strategic 'Day-1' entry into the GLP-1 therapy space. The product is priced competitively at INR 4,200 per month for both 2mg and 4mg strengths, targeting India's 101 million diabetic population. Developed entirely in-house from API to formulation, the launch demonstrates the company's advanced peptide science capabilities. This move positions Dr. Reddy's to capture significant market share in the high-growth metabolic disorder segment both in India and potentially global markets.

First DCGI-approved generic Semaglutide in India with 'Day-1' entry post-patent expiry
Phase-III clinical study involving 312 participants confirmed non-inferior efficacy and safety
Competitive monthly treatment cost of INR 4,200 for both 2 mg and 4 mg strengths
Fully integrated in-house development and manufacturing of both API and formulation
Targeting a massive addressable market of 101 million diabetics and 136 million pre-diabetics in India

💡 Investors should view this as a major growth driver given the first-mover advantage in the blockbuster GLP-1 category. Monitor the adoption rate in India and the company's upcoming generic semaglutide launches in international markets.

Dr. Reddy's Receives GST Tax Demand and Penalty of ₹2.20 Crore for FY 2019-22

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Mar 2026, 05:24 PM

Dr. Reddy's Laboratories has received three separate orders from the GST Authority in Chennai regarding tax demands for the period FY 2019-20 to FY 2021-22. The total penalty levied across these orders amounts to approximately ₹2.20 crore, with the bulk of the demand (₹2.19 crore) pertaining to FY 2019-20. The authority's orders are based on the classification of certain supplies as taxable under the TNGST Act. The company has clarified that these orders have no material impact on its financial or operational activities and it intends to file an appeal.

Total penalty of ₹2,20,03,734 levied by the Commercial Taxes Department, Chennai Intelligence-II.
Penalty for FY 2019-20 stands at ₹2,19,48,944, while FY 2020-21 and FY 2021-22 saw minor penalties of ₹50,406 and ₹4,384.
Orders were issued under Section 74 of the TNGST Act, 2017, regarding the taxability of certain supplies.
Company confirms no material impact on financials or operations and plans to file an appeal with the appellate authority.
The disclosure was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should view this as a routine regulatory matter as the penalty amount is negligible compared to the company's annual earnings. No immediate portfolio action is required based on this development.

Dr. Reddy's Partner Immutep Discontinues Phase III Lung Cancer Trial for Eftilagimod Alfa

🔴 NEGATIVE ⭐ 6/10

OTHER 📅 13 Mar 2026, 06:40 PM

Dr. Reddy's Laboratories has announced that the Phase III TACTI-004 trial for Eftilagimod Alfa (efti) will be discontinued following a planned interim futility analysis. The study was evaluating the drug for first-line non-small cell lung cancer, a key indication in Dr. Reddy's licensing agreement with Immutep. While Dr. Reddy's SA holds exclusive rights for the drug in regions excluding North America, Europe, Japan, and Greater China, the company has only made an upfront payment to date. This development represents a setback for the company's oncology pipeline in its licensed territories.

Independent Data Monitoring Committee (IDMC) recommended halting the TACTI-004 Phase III study due to futility.
The trial focused on Eftilagimod Alfa for patients with first-line non-small cell lung cancer.
Dr. Reddy's SA holds licensing rights for all countries outside North America, Europe, Japan, and Greater China.
Financial exposure is currently limited as only the initial upfront payment has been made to Immutep.
Immutep is conducting a comprehensive review to determine the next steps for the Eftilagimod Alfa program.

💡 Investors should note this R&D setback which may lead to a minor valuation adjustment for the specialty pipeline. Monitor for any potential write-offs of the upfront payment in upcoming quarterly results.

Dr. Reddy's Allots 10,275 Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Mar 2026, 12:27 PM

Dr. Reddy's Laboratories has allotted 10,275 equity shares of Re. 1 each to eligible employees on March 12, 2026. These shares were issued following the exercise of stock options under the company's 2002 and 2007 ESOP and ADR schemes. The total paid-up share capital of the company has increased to 83,46,53,295 equity shares. This is a routine administrative action and represents a negligible dilution of the existing share capital.

Allotment of 10,275 equity shares of face value Re. 1 each on March 12, 2026
Exercise price for the allotted shares was Re. 1 per share with nil premium
Total paid-up share capital increased to Rs. 83,46,53,295 post-allotment
Shares issued under the 2002 Employees Stock Options Scheme and 2007 ADR Stock Options Scheme

💡 This is a routine corporate update with no material impact on the company's valuation. Investors should maintain their focus on the company's core pharmaceutical operations and upcoming earnings reports.

Dr. Reddy's Wins Court Approval to Export Semaglutide to Non-Patent Markets

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 10 Mar 2026, 11:52 PM

Dr. Reddy's Laboratories has clarified that the Delhi High Court has ruled in its favor regarding the manufacture and export of Semaglutide. The Division Bench upheld a previous order from March 09, 2026, which allows the company to produce the drug in India for export to countries where Novo Nordisk does not hold patent registrations. This decision follows a legal challenge by Novo Nordisk, which sought an interim injunction against Dr. Reddy's. While the matter remains sub-judice, this ruling provides a significant pathway for Dr. Reddy's to enter the high-growth GLP-1 market internationally.

Delhi High Court Division Bench upheld the March 09, 2026, order allowing Semaglutide production.
Permission granted to export Semaglutide to international markets where Novo Nordisk lacks patent protection.
Court refused to grant an interim injunction requested by Danish pharmaceutical firm Novo Nordisk.
The ruling pertains to Semaglutide-containing products, a key category in diabetes and weight management.
Dr. Reddy's clarified that while the matter is sub-judice, the current ruling supports their manufacturing plans.

💡 Investors should monitor Dr. Reddy's progress in scaling Semaglutide exports to non-patent jurisdictions as it represents a major growth opportunity. The stock may see positive sentiment following this legal clearance for a high-demand product.

View All DRREDDY Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Global Generics (GG) revenue grew 17% in FY2025 to INR 32,553.5 Cr, while PSAI (Pharmaceutical Services and Active Ingredients) margins were 27.1%. In Q2 FY2026, total revenue reached INR 8,805 Cr, a 10% YoY increase driven by broad-based growth and the acquired Consumer Healthcare business.

Geographic Revenue Split

Revenue is diversified across North America, India, Europe, and Emerging Markets. North America and Europe experienced price erosion in FY2025, while India and Emerging Markets were bolstered by the acquisition of the Stugeron brand (INR 100 Cr revenue size).

Profitability Margins

Gross Profit Margin stood at 54.7% in Q2 FY2026, down from 59.6% YoY due to price erosion and product mix changes. Profit After Tax (PAT) for Q2 FY2026 was INR 1,437 Cr (16.3% margin), representing a 14% YoY increase.

EBITDA Margin

EBITDA margin for Q2 FY2026 was 26.7% (INR 2,351 Cr), a 174 bps decline YoY. The underlying EBITDA margin, adjusting for a one-time VAT provision, was 27.5%. Management targets a return to 25% EBITDA margins by FY2027 despite the tapering of high-margin Lenalidomide sales.

Capital Expenditure

Annual capex is projected between INR 1,500 Cr and INR 2,000 Cr, primarily funded through internal accruals. Historical capex was utilized for plant expansions and strategic brand acquisitions like the Nestlé Consumer Healthcare business.

Credit Rating & Borrowing

Maintains an [ICRA]AA+ (Stable) rating. Financial profile is robust with an interest coverage ratio of 46.4x and a total debt/OPBDITA of 0.3x as of FY2024. Net cash surplus stood at INR 2,751 Cr ($310 million) in Q2 FY2026.

⚙️ Operational Drivers

Raw Materials

Key inputs include Active Pharmaceutical Ingredients (APIs) and intermediates. Cost of Revenues reached INR 3,991 Cr in Q2 FY2026, a 23% YoY increase, reflecting higher volumes and the impact of acquired businesses.

Import Sources

Sourced globally to support 32 manufacturing and R&D facilities across 83 markets served. Specific country splits are not disclosed, but operations are exposed to global supply chain dynamics.

Capacity Expansion

Operates 32 manufacturing and R&D plants globally. Expansion is focused on complex generics, biosimilars, and capacity for the newly acquired Consumer Healthcare portfolio.

Raw Material Costs

Cost of revenues as a % of revenue increased to 45.3% in Q2 FY2026 from 40.4% YoY. Procurement strategies focus on internal API production (PSAI segment) to mitigate external price volatility.

Manufacturing Efficiency

Annualized RoCE stood at ~22% in Q2 FY2026, down from 28% in FY2025, reflecting the deployment of cash into lower-yielding immediate-term acquisitions.

Logistics & Distribution

Distribution spans 83 markets. Selling, General & Administrative (SG&A) expenses were INR 2,644 Cr in Q2 FY2026 (30% of revenue), up 15% YoY due to investments in the consumer healthcare business.

📈 Strategic Growth

Expected Growth Rate

13-15%

Growth Strategy

Growth is driven by a 'triple-play' strategy: strengthening the core generics business, advancing a complex pipeline (Semaglutide, Abatacept), and aggressive M&A. Recent deals include the Nestlé Consumer Healthcare acquisition and the Stugeron brand for INR 420 Cr ($50M).

Products & Services

Generic medicines (Lenalidomide capsules), APIs, Biosimilars (Semaglutide), and Consumer Healthcare products (NRT business, Stugeron).

Brand Portfolio

Stugeron, Revlimid (generic version: Lenalidomide).

New Products/Services

Launched Lenacapavir for HIV prevention in LMICs. 85 filings are pending US FDA approval, including 17 expected First-to-File (FTF) statuses which provide 180-day exclusivity and higher revenue potential.

Market Expansion

Expanding presence in India and Emerging Markets through brand acquisitions. The Stugeron acquisition targets the India and Emerging Markets vertigo treatment segment.

Market Share & Ranking

Established as one of the leading Indian pharmaceutical companies with a presence in 83 markets.

Strategic Alliances

Partnered with Unitaid, Clinton Health Access Initiative, and Wits RHI for HIV tools. Collaborating with Nestlé for the Nutraceuticals subsidiary (49% ownership by Nestlé India).

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and biosimilars (e.g., Semaglutide) as simple generics face 10-15% annual price erosion. Dr. Reddy's is positioning itself through 17 potential FTF filings to capture high-value windows.

Competitive Landscape

Faces intense competition in the US generics market from other Indian and global players, leading to price erosion in select products.

Competitive Moat

Moat is built on R&D scale (7-9% of revenue) and a massive filing pipeline (85 pending approvals). This is sustainable due to a net cash position of INR 2,751 Cr, allowing for continuous reinvestment without debt pressure.

Macro Economic Sensitivity

Vulnerable to global healthcare policy changes and inflation in raw material costs which increased cost of revenues by 23% YoY in Q2 FY2026.

Consumer Behavior

Increasing demand for affordable HIV prevention (Lenacapavir) and weight management (Semaglutide) is shaping the R&D pipeline.

Geopolitical Risks

Operations in 83 markets expose the company to trade barriers and regulatory scrutiny from the US FDA, US SEC, and US DoJ.

⚖️ Regulatory & Governance

Industry Regulations

Subject to US FDA, US SEC, and US DoJ scrutiny. Successfully resolved past non-compliances, but ongoing maintenance of high manufacturing standards is critical to avoid import bans.

Environmental Compliance

Targeting carbon neutrality in Scope 1 and 2 by 2030. Achieved water positivity and 42% renewable power usage as of FY2023.

Taxation Policy Impact

Effective tax rate was 22.2% in Q2 FY2026 (INR 408 Cr). FY2025 tax expense was INR 1,953.9 Cr (25.4% of PBT).

Legal Contingencies

Faces ongoing investigations and product litigations. An impairment charge of INR 66 Cr was taken in Q2 FY2026, including INR 54 Cr for the Middleburgh facility following the discontinuation of the Conjugated Estrogen pipeline product.

⚠️ Risk Analysis

Key Uncertainties

Adverse outcomes from ongoing lawsuits or US FDA inspections could significantly impact liquidity and market access. Tapering of Lenalidomide revenue poses a margin risk (potential drop below 25% EBITDA).